arsenic trioxide has been researched along with lovastatin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Higashi, Y; Pallis, M; Russell, N; Turzanski, J | 1 |
| Chng, WJ; Lau, LG; Mow, BM; Yusof, N | 1 |
| Ebert, SN; Katchman, AN; Koerner, J; Tosaka, T; Woosley, RL | 1 |
| Brossart, P; Fröhlich, E; Wahl, R | 1 |
3 review(s) available for arsenic trioxide and lovastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.
Topics: Acute Disease; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Division; Ceramides; Child; Cyclosporine; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Leukemia, Myeloid; Lovastatin; Multicenter Studies as Topic; Neoplasm Proteins; Oxides; Phenotype; Protein Kinase C; Randomized Controlled Trials as Topic; Signal Transduction; Tumor Cells, Cultured | 2002 |
Targeted therapy in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; DNA, Antisense; Drug Delivery Systems; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Lovastatin; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
3 other study(ies) available for arsenic trioxide and lovastatin
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Haloperidol; Humans; Loratadine; Lovastatin; Methadone; Oxides; Pentamidine; Potassium Channel Blockers; Rabbits; Terfenadine; Torsades de Pointes | 2006 |
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Iodides; Lovastatin; Neoplasm Metastasis; Oxides; Pyrazines; Sirolimus; Thymus Gland; Thyroid Neoplasms; Tretinoin | 2009 |